VolitionRx Receives NYSE Warning, Must Submit Compliance Plan

VolitionRx received a notice from the NYSE American stating that the company is not in compliance with the NYSE American continued listing standards requiring a company to have stockholders' equity of at least $2.0M if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, requiring a company to have stockholders' equity of at least $4.0M if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years and requiring a company to have stockholders' equity at least $6.0M if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The Notice also indicates that the company is also not currently eligible for any exemption in the Company Guide. The company must submit a plan to the NYSE American by March 8 advising of actions it has taken or will take to regain compliance with the continued listing standards by August 6, 2027. If the NYSE American determines to accept the Plan, the company will be subject to periodic reviews, including quarterly monitoring for compliance with the Plan. If the company does not submit a plan or if the Plan is not accepted, NYSE American will commence delisting proceedings. Furthermore, if the Plan is accepted but the company is not in compliance with the continued listing standards by August 6, 2027 or if the company does not make progress consistent with the Plan, the NYSE American will initiate delisting proceedings as appropriate. The notice has no immediate impact on the listing of the company's shares of common stock. The company intends to submit a plan to the NYSE American on or before March 8 that will regain compliance with the NYSE American continued listing standards by August 6, 2027.